Abstract 2077P
Background
To investigate the efficacy of Superoxide Dismutase (SOD, 70 UI), Palmitoyethanolamide (PEA, 300 mg) Alpha Lipoic Acid (ALA, 300 mg),vitamins B6 (1.5 mg), B1 (1.1 mg), B12(2.5 mcg), E (7.5 mg), Nicotinamide (9 mg) and minerals (Mg 30 mg, Zn 2,5 mg) in one tablet in managing neuropathic pain due to cancer chemotherapy.
Methods
In this pilot study, 67 age-matched patients with cancer (41 men) and a mean age of 65.4 years were randomly assigned, either to receive the combination of ten elements (2 tablets/24h) in the active A group, (n=33), or the placebo B (n=34) for six months. Nerve function was assessed by DPN Check [sural nerve conduction velocity (SNCV) and amplitude (SNAP)]. Sudomotor function was evaluated with SUDOSCAN, which measures electRochemical skin conductance in hands and feet (ESCH and ESCF). We used Pain questionnaires: Pain Detect (PD), Neuropathic Pain Symptom Inventory (NPSI), and Visual Analog Scale (VAS) for the estimation of neuropathic pain, also. All patients received Taxanes and platinum analogs as cancer chemotherapy.
Results
At follow-up, measurements from SNCV, SNAP, ESCH and ESCF did not change significantly in both groups. In A group PD baseline vs. final (9.57±7.0 vs. 6.78±4.16, p=0.003), NPSI (28.51±21.26 vs. 19.87±12.6, p<0.001) and VAS (27.78±22.40 vs 21.48±17.79, p=0.003) improved significantly during follow up. In group B PD (7.03±5.19 vs. 9.71±6.61 p<0.001), NPSI (23.50±18.99 vs. 36.25±22.15, p<0.001), and VAS (25.03±23.83 vs 38.75±26.60 p<0.001) deteriorated. No side effects detected.
Conclusions
The combination of the ten elements as supplement in one tablet for six months at a daily dose of two pills in patients improved neuropathic pain due to cancer chemotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2028TiP - Phase I, non-randomised, open-label, multi-centre dose escalation trial of BI 764532 (DLL3/CD3 IgG-like T cell engager [TcE]) + ezabenlimab (anti-PD-1 antibody) in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs) expressing DLL3
Presenter: Julien Mazieres
Session: Poster session 06
2029TiP - Phase I study of ABBV-706, an anti-SEZ6 antibody-drug conjugate, alone or in combination in adults with advanced solid tumors
Presenter: Sreenivasa Chandana
Session: Poster session 06
2035P - Routine biomarker monitoring does not replace comprehensive clinical assessment in the detection of immunotherapy induced myocarditis
Presenter: Alexandra Johnson
Session: Poster session 06
2036P - Prevalence and risk evaluation of cardiovascular disease among newly diagnosed prostate cancer population in China
Presenter: Weiyu Zhang
Session: Poster session 06
2037P - Prehabilitation as a strategy to improve postoperative outcomes in frail cancer patients undergoing elective surgery: A systematic review and meta-analysis
Presenter: Muhammed Elfaituri
Session: Poster session 06
2039P - Primary endpoints of confirmatory randomized controlled trials for older patients with cancer: A scoping review
Presenter: Tomonori Mizutani
Session: Poster session 06
2041P - The prevalence of hematologic adverse events (HAEs) and myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) in patients (pts) with advanced high grade ovarian carcinoma (aHGOC) receiving PARP inhibitor (PARPi), with or without a germline BRCA pathogenic variant
Presenter: Carmine Valenza
Session: Poster session 06
2042P - Improving breast cancer outcomes for indigenous women
Presenter: Vita Christie
Session: Poster session 06
2043P - Can Charlson Comorbidity Index (CCI) and Clinical Frailty Scale (CFS) assessments predict survival in octogenarians with colorectal cancer?
Presenter: Neda Nikolic
Session: Poster session 06
2044P - Bloodstream infections (BSI) in cancer patients: Epidemiology, antibiotic therapy and risk factors related to mortality
Presenter: Carlos López Jiménez
Session: Poster session 06